Lee et al. found that CSF VILIP-1 levels are significantly higher in AD patients compared with controls and that the diagnostic performance of VILIP-1 is similar to CSF Aβ42, t-tau, or p-tau [56]. This evidence concerns the gene MAPT and Alzheimer disease.